1
|
Zhong J, Ali K, Yang P, Zhao X, Wu L. Successful Treatment of Chronic Actinic Dermatitis with Tofacitinib. Clin Cosmet Investig Dermatol 2024; 17:399-407. [PMID: 38352065 PMCID: PMC10863493 DOI: 10.2147/ccid.s451824] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2023] [Accepted: 02/06/2024] [Indexed: 02/16/2024]
Abstract
We present the case of a 58-year-old male patient who presented with pruritic skin plaques and papules on the scalp, face, back, and back of the hands for over a year. The symptoms worsened upon exposure to sunlight and improved on cloudy days. Despite previous attempts at treatment with glucocorticoid ointment and antihistamine drugs, the patient experienced progressive aggravation of symptoms. Physical examination revealed hypertrophic and infiltrating nodules, with significant scratches and local exudation. Skin biopsy confirmed the diagnosis of sun-induced dermatosis. The patient was initiated on tofacitinib, an oral Janus Kinase inhibitor, along with a halometasone ointment, oral ebastine tablets, and strict sun protection. Over the course of four revisits spanning four months, the patient experienced a significant improvement in symptoms, with the rash almost disappearing and pruritus subsiding. The treatment was well tolerated and no adverse effects were observed. Follow-up for six months post-treatment showed no recurrence of symptoms. This case highlights the efficacy of tofacitinib in managing sun-induced pruritic plaques and suggests it as a potential therapeutic option in similar cases.
Collapse
Affiliation(s)
- Jianbo Zhong
- Department of Dermatology, Affiliated Hangzhou First People’s Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, People’s Republic of China
| | - Kamran Ali
- Department of Dermatology, Affiliated Hangzhou First People’s Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, People’s Republic of China
- Department of Oncology, the Fourth Affiliated Hospital, International Institutes of Medicine, Zhejiang University School of Medicine, Yiwu, Zhejiang, People’s Republic of China
| | - Ping Yang
- Department of Dermatology, Affiliated Hangzhou First People’s Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, People’s Republic of China
| | - XingYun Zhao
- Department of Dermatology, Affiliated Hangzhou First People’s Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, People’s Republic of China
| | - LiMing Wu
- Department of Dermatology, Affiliated Hangzhou First People’s Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, People’s Republic of China
| |
Collapse
|
2
|
Chen JC, Lian CH. Chronic actinic dermatitis in an old adult significantly improved by dupilumab. PHOTODERMATOLOGY, PHOTOIMMUNOLOGY & PHOTOMEDICINE 2022; 38:176-177. [PMID: 34494309 DOI: 10.1111/phpp.12731] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/20/2021] [Revised: 08/18/2021] [Accepted: 09/05/2021] [Indexed: 02/05/2023]
Affiliation(s)
- Jin-Chun Chen
- Department of Dermatology and Venereology, Shenzhen Second People's Hospital (a.k.a Shenzhen University First Affiliated Hospital, the First Affiliated Hospital of Shenzhen University Health Science Center), Shenzhen, Guangdong, China
- Shantou University Medical College, Shantou, China
| | - Cui-Hong Lian
- Department of Dermatology and Venereology, Shenzhen Second People's Hospital (a.k.a Shenzhen University First Affiliated Hospital, the First Affiliated Hospital of Shenzhen University Health Science Center), Shenzhen, Guangdong, China
| |
Collapse
|
3
|
Nassim D, Alajmi A, Jfri A, Pehr K. Apremilast in dermatology: A review of literature. Dermatol Ther 2020; 33:e14261. [PMID: 32876993 DOI: 10.1111/dth.14261] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2020] [Revised: 08/23/2020] [Accepted: 08/26/2020] [Indexed: 01/10/2023]
Abstract
Apremilast is an orally administered small molecule that specifically inhibits the phosphodiesterase-4 enzyme and modulates the immune system by increasing the levels of intracellular cyclic adenosine monophosphate (cAMP) and inhibiting IL-2 & 8, interferon-γ and tumor necrosis factor (TNF) production. It is FDA approved for the treatment of psoriasis, psoriatic arthritis, and oral ulcers of Behcet's disease. More recently, apremilast has been used off-label to treat varied dermatological diseases where systemic corticosteroids or immunosuppressive agents were not effective. We review the efficacy and safety of apremilast in the treatment of aphthous stomatitis, Behçet's disease, chronic actinic dermatitis, atopic dermatitis, cutaneous sarcoidosis, hidradenitis suppurativa, lichen planus, and discoid lupus erythematosus in cases where standard treatment has failed.
Collapse
Affiliation(s)
- David Nassim
- Faculty of Medicine, McGill University, Montreal, Quebec, Canada
| | - Ali Alajmi
- Division of Dermatology, McGill University, Jewish General Hospital, Montreal, Quebec, Canada
| | - Abdulhadi Jfri
- Division of Dermatology, McGill University, Jewish General Hospital, Montreal, Quebec, Canada
| | - Kevin Pehr
- Division of Dermatology, McGill University, Jewish General Hospital, Montreal, Quebec, Canada
| |
Collapse
|